UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 20, 2010

NABI BIOPHARMACEUTICALS

(Exact Name of Registrant as specified in its charter)

12276 Wilkins Avenue, Rockville, Maryland 20852

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (301) 770-3099

Not Applicable

(Registrant’s name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

The following provides a summary of votes cast for the proposals on which the stockholders of Nabi Biopharmaceuticals (the “Company”) voted at the annual meeting of stockholders held on May 20, 2010 (the “Annual Meeting”):

Proposal 1. Election of seven directors to serve terms until the next annual meeting of stockholders and the election of their successors.

Proposal 2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 25, 2010

At the Annual Meeting, Peter B. Davis received less than a majority of the total votes cast with respect to his re-election as a director. Promptly following the Annual Meeting, Mr. Davis tendered his resignation as required by the Company’s Corporate Governance Principles. In accordance with those Principles, the Nominating and Governance Committee promptly met in person to consider whether to recommend acceptance or rejection of Mr. Davis’ tendered resignation to the full Board of Directors, which is charged under the Principles with making that determination. The Nominating and Governance Committee recommended to the Board of Directors that it reject Mr. Davis’ tendered resignation. The Board of Directors met in person promptly after the meeting of the Nominating and Governance Committee to consider its recommendation, and review the facts and circumstances relevant to the stockholder vote. Considering the best interests of the Company and its stockholders and other factors, the Board of Directors rejected Mr. Davis’ resignation, noting Mr. Davis’ significant contributions to the Company, the Board of Directors, the Audit Committee, and various committees of the Board in connection with the Company’s strategic alternative as well as his financial background and expertise. Mr. Davis did not take part in either the Nominating and Governance Committee or the Board’s deliberations.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 26, 2010